Key Takeaways
- Revenue up 15% YoY, but margins collapsed: EBITDA margin fell from 23% to 15% YoY as a brutal combination of spiking input costs, old inventory clearance, and a goodwill pricing stance wiped out profitability.
- The margin hit is temporary and self-inflicted: Management chose to absorb a 200%+ spike in solvent costs rather than pass it to customers, while simultaneously clearing high-cost SDA inventory; both headwinds are expected to clear by Q1 FY24.
- A multi-year growth engine is being assembled: Electrolyte salts, flame retardants, continuous flow pharma intermediates, and BS-VII SDA approvals are all progressing from trials toward commercialization, supporting a revenue target of ₹800-850 crore by FY25/26.
- Capacity is the binding constraint on ambition: Management states current infrastructure maxes out at ₹850-950 crore in revenue; a greenfield project requiring 30 months and fresh capital is the only path beyond that, with a decision expected in the next couple of quarters.
- What to watch next quarter: Whether Q4 margins show the promised "couple of percentage points" improvement, any update on the greenfield capex decision, and the pace of SDA demand recovery as the large Chinese customer is expected to resume procurement from May.
Margin Destruction: The Q3 Story
- Input cost shock: Solvent prices spiked over 200% in many cases and bromine prices rose 20-25%, while freight costs also climbed; these ancillary costs are not part of customer pricing formulas, so the company had no contractual mechanism to pass them through.
- Goodwill absorption: Management made a deliberate choice to absorb these costs rather than approach customers for price increases, citing a moral responsibility to support Eurozone and Japanese customers who were already hurting from sharp currency appreciation and had supported Tatva Chintan during past pricing issues.
- Inventory clearance drag: The company was sitting on piled-up SDA inventory, both finished goods and in-process materials. Converting in-process materials to finished goods forced the absorption of elevated solvent and commodity costs with no significant reason to ask customers for a price rise.
- Low plant occupancy: When plant occupancy falls below 80-85%, real margins do not settle in because many overheads and direct costs are fixed in nature; Q3 involved clearing old inventory rather than running rampant production.
- Margin recovery path: The inventory that hurt margins should last until the current quarter, after which solvent and commodity prices are falling back in line; management expects a return to a normal margin run rate of 22%+ from Q1 FY24, with Q4 FY23 seeing only a couple of percentage points of improvement.
Chintan Shah: "It was also kind of a moral responsibility from our part, to kind of absorb. And they have always supported us in our past issues, whenever we had pricing issues, they have been upfront in supporting us. So, now it was a time for us to step up and support them, and we did that."
SDA: Demand Trough and Recovery Bet
- Current demand is subdued: Overall SDA market demand is not back to normal levels yet; one very large customer from China is still struggling with demand and piled-up inventory due to long shutdowns and a large drop in heavy-duty vehicle sales in China.
- Geographical concentration: 90-100% of products made using Tatva Chintan's SDAs currently find applications in India and China because US, Europe, and Japan approvals were already held by competitors when the company started; BS-VII approvals will remove these geographical barriers.
- Pricing is holding: Finished goods selling prices for SDAs have not been reduced or dropped; prices remain stable despite the demand weakness.
- Recovery timeline: The large Chinese customer is expected to resume procurement from May 2023, with strong sales anticipated from May/June onwards; management expects SDA demand to remain at nearly similar levels for the next two quarters before volumes rebound strongly from July onwards.
- New product pipeline: Successfully supplied plant-scale trial material of a new SDA to a new customer, and offered the opportunity to supply a second SDA on plant-scale trial during Q4 FY23; approvals for both new SDAs are expected by September 2023.
- Euro VII catalyst: Completed development and commercial scale-up of Euro VII SDAs; one has been supplied, a second is about to be dispatched, and all potential candidates for Euro VII SDAs are in place.
Chintan Shah: "We are confident that the volumes in SDAs will rebound strongly from July onwards and we remain optimistic about increasing volumes over the coming years."
New Growth Engines: Electrolyte Salts, Flame Retardants, and Continuous Flow
- Electrolyte salts milestone: Shipped the first small-scale trial order from the pilot plant in January 2023, successfully meeting the most stringent quality requirements; a plant-scale trial order is anticipated in June 2023 with formal approval to follow.
- Electrolyte salts customer pipeline: The large customer whose offtake is currently on hold for debottlenecking is expected to resume from end of June 2023; a separate energy storage customer is running trials with the US Energy Department, with approvals expected by July/August 2023 and good business from September 2023 onwards.
- Electrolyte solution progress: Successfully supplied electrolyte solution to the same super-capacitor customer who approved the electrolyte salts; pilot-scale systems are deployed and work is underway to convert to plant scale, with a plant-scale trial order of 8-10 MT expected.
- Flame retardants nearing commercialization: Full-scale approval received from two customers with pricing negotiations underway; four more approvals are awaited; full-scale trial supply to two customers is planned in Q4 FY23, with commercialization expected from Q1 FY24.
- Continuous flow chemistry: A second product on continuous flow basis received quality approval from small-scale plant trial material much faster than anticipated; plant-scale trial material is planned by end of August 2023, with commercial supplies strongly expected post April 2024.
- Pharma intermediate timeline: Plant-scale trial material for one pharmaceutical intermediate was submitted last quarter; commercialization is expected by end of 2024 given the time-consuming pharma approval process.
- Segment confidence: Management is confident of delivering exponential growth in electrolyte salts over the next three years and very confident about strong growth in pharma and agro intermediates over the coming years.
PASC: A Temporary Air Pocket in a Strong Story
- Q3 revenue pressure: PASC segment revenue was under pressure because one US pharma customer postponed November-December orders to April, and a large agrochemical customer's pending orders from a Chinese supplier arrived simultaneously, with 6-7 containers hitting Indian shores at once and creating temporary oversupply.
- Demand outlook is robust: Management sees very strong demand in PASC growing exponentially over the years, describing it as "something very difficult to digest, but that is what actually the industry is looking for." Revenue is expected to return to ₹40-45 crores in H1 FY24.
- Commercial supply timeline: For products currently in plant-scale trial and approval stages, commercial supplies are expected to kick in by mid-2024.
Chintan Shah: "In PASC, we see a very strong demand growing exponentially over the years. So, this is something very difficult to digest, but that is what actually the industry is looking for."
Capacity, Capex, and the Growth Ceiling
- Current infrastructure maxes out: Management states the existing infrastructure can reach a maximum of ₹850-950 crore in revenue; beyond that, the company will run short on capacity.
- Revenue target: A conservative but fair estimate places revenue in the zone of ₹800-850 crore by FY25/FY26; the opportunity is much larger but ramp-up will be gradual over 3-4 years, and plant capacities will not support going beyond that without a greenfield project.
- Greenfield decision pending: Internal discussions on plant design concepts and infrastructure requirements have begun; a decision to proceed with new capex is expected "probably in the next couple of quarters," with management acknowledging "probably we have no choice, but we have to move ahead with that decision."
- Greenfield timeline and scope: The project would take at least 24-27 months from ground-breaking to completion; the new facility will focus on continuous flow chemistries and downstream products, with safety production capability offering security of supply across all segments, and will also include SDAs and electrolyte salts.
- Funding path: Management may look to raise fresh capital for the greenfield expansion over the next few quarters; equity dilution is "definitely the option which we would like to explore," and some dilution will also be required by mid-next year to meet the 75% public holding requirement.
- Near-term capacity additions: The Dahej SEZ plant capex is completed with trial runs underway and commercial production targeted by February 1st; the R&D facility expansion at Vadodara is at the finishing stage.
- Solvent recovery savings: One solvent recovery system is already implemented, reducing effective usage of approximately 800 MT per year for one solvent; a second system is installed with trials starting mid-February 2023, enabling simultaneous recovery and reuse of both large-volume solvents from the Dahej plant.
Chintan Shah: "Though it is conservative, but it is a very fair estimate to put in place -- and in any case, we will not have enough plant capacities to go beyond that. So, for that, the Greenfield project has to be developed and then only it can take us further beyond INR 900 crores, INR 950 crores revenue."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue | Close FY23 with revenue in excess of ₹400 crore | FY23 end |
| Revenue | Flattish growth for next 2 quarters; decent growth next financial year | Q4 FY23 and Q1 FY24; FY24 |
| Revenue | Reach ₹800-850 crore (constrained by existing capacity) | FY25/FY26 |
| EBITDA margin | Return to normal run rate of 22%+ | Q1 FY24 |
| EBITDA margin | Q4 FY23 sees a couple of percentage points gain, but not 22-23% | Q4 FY23 |
| SDA demand | Large Chinese customer resumes procurement; strong sales return | May/June 2023 |
| SDA demand | Volumes rebound strongly | July 2023 onwards |
| SDA approvals | Approvals for two new SDAs | By September 2023 |
| Flame retardants | Commercialization begins | Q1 FY24 |
| Electrolyte salts | Large customer resumes offtake | End of June 2023 |
| Electrolyte salts | Energy storage customer approvals received; good business begins | July/August 2023; September 2023 onwards |
| PASC revenue | Returns to ₹40-45 crore | H1 FY24 |
| Continuous flow product | Plant-scale trial material supplied; commercial supplies begin | End of August 2023; post April 2024 |
| Pharma intermediate | Commercialization | End of 2024 |
| Greenfield capex | Decision to proceed | Next couple of quarters |
| Greenfield construction | Completion from ground-breaking | 30 months |
| Environmental clearance | Received for greenfield site | By March 2023 |
| Fundraising | Equity dilution to meet 75% public holding and fund greenfield | Mid-next year and next few quarters |
Key Metrics
| Metric | Q3 FY23 |
|---|---|
| Revenue from operations | ₹120.6 cr, +15% YoY |
| EBITDA | ₹17.9 cr, -25% YoY |
| EBITDA margin | 15%, vs 23% in Q3FY22 |
| PAT | ₹11.6 cr, -49% YoY |
| PAT margin | 10%, vs 22% in Q3FY22 |
| Other income | -67% YoY, decline due to lower FD income and absence of ₹2.8 cr forex gain in base quarter |
| Exports (9MFY23) | ₹209.5 cr, 70% of revenue |
| FY23 revenue guidance | In excess of ₹400 cr, with subdued profitability vs FY22 |
| FY25/FY26 revenue estimate | Upward of ₹800 cr to ₹850 cr, constrained by existing infrastructure capacity |
| PTCs revenue | ₹32.5 cr, ~35% of total revenue; 9MFY23 growth of 55% YoY |
| Electrolyte Salts revenue | ₹4.1 cr, ~5% of total revenue; 9MFY23 growth of 357% YoY |
| Pharma and Agro Intermediates and Specialty Chemicals revenue | ₹26.4 cr, ~35% of total revenue; 9MFY23 growth of 36% YoY |
| SDAs revenue | ₹57.1 cr, ~24% of total revenue; 9MFY23 decline of 61% YoY |
| Consolidated inventory | ₹176.2 cr, down from ₹2,030 cr during the quarter |
| IPO funds utilized | 93% (₹192.7 cr of ₹207.28 cr) as on 31 December 2022 |